Loading patent…
AssigneeEir Biotherapies Srl
InventorsGiulia Golinelli, Giulia Grisendi, Carlotta Spano, Olivia Candini, Massimo Dominici
Estimating the term…
Method for the production of bi-functional cells comprising engineering a starting cell population with a phenotype attributable to human pericytes extracted from adipose tissue (AD-PC), obtaining engineered cells, known as bi-functional AD-PCs, expressing (which means that they produce) simultaneously both the anti-tumor molecule TRAIL and also the truncated form of a chimeric receptor targeted against the GD2 antigen (GD2 tCAR); this dual targeting (understood as reaching a specific target), based on affinity and mediated by both TRAIL and also GD2 tCAR, supports the prediction of combining site-specificity with a prolonged retention of AD-PCs in tumors expressing the antigen GD2, so as to achieve a more effective release of TRAIL for still incurable tumors.
1-19. (canceled)
A method for producing bi-functional cells, comprising engineering pericytes (PCs) to obtain engineered PCs contemporarily expressing both Tumor necrosis factor-Related Apoptosis-Inducing Ligand (TRAIL) and a truncated chimeric antigen receptor (tCAR) directed against disialoganglioside (GD2) (GD2 tCAR), wherein the tCAR comprises a single-chain fragment variable (scFv) directed toward the GD2, the tCAR does not comprise any intracell signal transduction domains, and said PCs are cells of human adipose tissue (AD-PC).
Dependencies are inferred from the claim text.